Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion~* Pathologically confirmed invasive breast cancer with ER \< 10%, PR \< 10%, by IHC, HER2 1+ or 0 or FISH negative~* Measurable (\>= 1 cm) or assessable disease detectable by imagining or physical exam~* Patients with bone only disease have measurable lesions on x-ray, MRI, or CT scan~* Only one or no prior therapy for metastatic or recurrent breast cancer is allowed~* Prior chemotherapy or radiation therapy is permitted but at least 2 weeks should elapse prior to study enrollment~* Prior therapy with bevacizumab is permitted but at least 2 weeks should elapse prior to study enrollment~* Prior therapy with bevacizumab is permitted but at least 28 days should elapse from the last bevacizumab treatment prior to study enrollment~* ECOG PS or 0-1~* Signed protocol specific informed consent prior to registration~* Life expectancy greater than 3 months~* Please contact study investigator and/or consult the protocol document for specific laboratory criteria~* Tissue block available from primary breast cancer~* Premenopausal women must have a negative serum or urine pregnancy test prior to starting on study treatment (post-menopausal is defined as \> 6 months of amenorrhea prior hysterectomy)~Exclusion~* More than or equal to 2 prior regimens for metastatic breast cancer~* Leptomeningeal disease~* Brain metastasis except for a solitary lesion that was resected or treated with gamma knife with no residual disease on CT or MRI or received whole brain RT and f/u MRI was normal with no residual neurologic deficit~* History of interstitial lung disease (ie pneumonitis, pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest computerized tomography (CT) scan~* History of irreversible neuropathy~* Another malignancy other than carcinoma in situ of the cervix or skin cancer~* Active uncontrolled bacterial viral or fungal infection~* Active pregnancy or breast feeding~* Patients with pre-existing neuropathy \>= grade 2~* History of myocardial infarction, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia~* Patients with previous history of CTCAE grade \>= 3 hypersensitivity to paclitaxel or Cremophor EL are not eligible

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Patients receive paclitaxel IV and carboplatin IV on days 1, 8, and 15. Patients also receive panitumumab IV on days 1 and 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).